Rhett Johnson

Digital therapeutics (DTx) leverage technology to deliver evidence-based treatments. Due to reimbursement barriers and slow market adoption, players in the space are pivoting to new business models. This article shares details. Broadening User Requirements When Selecting Valves For Medical Devices By broadening the scope of user requirements, one can ensure that a valve will function as expected over the device’s entire life cycle — from manufacturing through clinical use.

By Rhett Johnson, Andrew Parece, and Lorenzo D’Angelo, Charles River Associates Digital therapeutics (DTx) leverage technology to deliver evidence-based treatments for various health conditions, aiming to complement or replace traditional treatments with personalized, scalable, and cost-effective interventions. Despite regulatory hurdles, reimbursement barriers and slow market adoption, the DTx industry has made remarkable progress, securing more than $50 billion in funding back in 2021.

Since passage of the Inflation Reduction Act (IRA) in August 2022, the focus of many industry analysts and pharmaceutical companies has been on two important first order concerns: identifying products to be negotiated by the Centers for Medicare & Medicaid Services (CMS) and assessing the direct impact on prices. Most companies have now completed the critical analyses associated with these direct effects.